News

Media and Political Bulletin – 10 September 2020

Media and Political Bulletin

10 September 2020

Media Summary

MHRA investigates medicines that left supply chain as FMD alert issued

Chemist+Druggist, Eliza Slawther, 09 September 2020

Chemist+Druggist reports that the Medicines and Healthcare products Regulatory Agency (MHRA) is investigating circumstances under which multiple medicines left the supply chain before entering it again.

The products were reintroduced into the supply chain by Kingsley Specials after it purchased them from a company that does not “hold a wholesale dealers authorisation”, the MHRA said in the alert. The company subsequently “sold [them] on to a number of other wholesalers”, it added.

Wholesalers and healthcare professionals have been told to check their stocks and all the listed products – available in full on the alert – for the relevant batches supplied from wholesalers Smartway Pharmaceuticals, Drugsrus and Optimal Pharma.

Parliamentary Coverage

UK Internal Market Bill introduced today

Office of the Secretary of State for Scotland, Cabinet Office, Department for Business, Energy & Industrial Strategy, The Rt Hon Michael Gove MP, The Rt Hon Alister Jack MP, and The Rt Hon Alok Sharma MP, 09 September 2020

The UK Internal Market Bill – a new Bill to protect jobs and trade across the whole of the UK after the Transition Period ends – was introduced to Parliament yesterday.

From 1 January 2021, powers in a range of policy areas previously exercised at an EU level will flow directly to the devolved administrations in Holyrood, Cardiff Bay and Stormont, guaranteeing companies can trade unhindered across all 4 parts of the UK.

The Bill will also set out steps to ensure that the government is able to deliver on its commitments to the people of Northern Ireland.

A new independent Office for the Internal Market (OIM) is to be set up within the Competition and Markets Authority (CMA) to monitor the smooth running of trade within the UK.

Full Coverage

MHRA investigates medicines that left supply chain as FMD alert issued

Chemist+Druggist, Eliza Slawther, 09 September 2020

The Medicines and Healthcare products Regulatory Agency (MHRA) is investigating circumstances under which multiple medicines left the supply chain before entering it again.

The medicines watchdog is “investigating an incident where several medicines appear to have left the legal supply chain and have then been re-introduced via [the wholesaler] Kingsley Specials”, it said as a falsified medicines directive (FMD) alert was issued last week (September 1).

The products were reintroduced into the supply chain by Kingsley Specials after it purchased them from a company that does not “hold a wholesale dealers authorisation”, the MHRA said in the alert. The company subsequently “sold [them] on to a number of other wholesalers”, it added.

Kingsley Specials has had its license to trade suspended while the watchdog investigates the incident, an MHRA spokesperson told C+D last week (September 3). C+D has contacted Kingsley Specials, but the company declined to comment while the investigation is ongoing.

The products involved “appear to be genuine, with legitimate batch numbers and safety features”, the MHRA said. However, they “are thought to have left the legitimate supply chain and been reintroduced between March and August,” it added.

“This means that the correct transport and storage conditions cannot be guaranteed and, while unlikely, could impact their effectiveness,” the MHRA explained.

The affected products are listed in appendix two of the MHRA’s alert. Some of the products included in the alert are Eliquis, Stelara and Zebinix.

Affected medicines should be quarantined and reported

Wholesalers and healthcare professionals have been told to check their stocks and all the listed products – available in full on the alert – for the relevant batches supplied from wholesalers Smartway Pharmaceuticals, Drugsrus and Optimal Pharma.

The three companies – who did not purchase directly from Kingsley Specials but via intermediate companies – are “not implicated in any wrongdoing and are co-operating with the MHRA to resolve the matter,” the MHRA stressed.

Smartway Pharmaceuticals, Drugsrus and Optimal Pharma have also “implemented safety measures by decommissioning the impacted packs [and] changing the status to stolen/inactive in the National Medicines Verification System”, the MHRA said.

If any affected products are identified by healthcare providers, they are asked to quarantine these packs, and notify the Defective Medicines Report Centre, the MHRA said.

Healthcare professionals dispensing the affected products should “ensure that appropriate scanning takes place at the point of dispensing” and not dispense goods that flag as “stolen” or “inactive”, the MHRA said.

“Where there is no ability for scanning, healthcare professionals and wholesalers should consider using the unique serial number or product code or global trade item number information available on the outer packaging of the product,” it added.

Smartway: Customers have been alerted

Smartway has “effective traceability for the affected stock”, which has allowed it “to identify affected customers”, a spokesperson for the company told C+D yesterday (September 8).

It has “contacted this small group [of customers] with specific instructions” and if any customers “did not receive information” from Smartway on August 21, they can “assume that any products from [it] are unaffected”, the spokesperson added.

However, pharmacy teams should “check to see whether they have purchased products from other wholesalers named on the alert and follow the instructions,” the spokesperson added.

Drugrus told C+D today (September 9) that it can “confirm that Drugsrus had no part in any wrongdoing and is co-operating fully with the MHRA to help resolve the matter”.

C+D also contacted Optimal Pharma, who declined to comment as the matter is still under MHRA investigation.

Media and Political Bulletin – 10 September 2020

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?